11月21日，科美诊断跌5.22%，成交额5332.56万元。两融数据显示，当日科美诊断获融资买入额594.64 万元，融资偿还547.48万元，融资净买入47.16万元。截至11月21日，科美诊断融资融券余额合计1.65亿 元。 融资方面，科美诊断当日融资买入594.64万元。当前融资余额1.65亿元，占流通市值的5.38%，融资余 额低于近一年30%分位水平，处于低位。 资料显示，科美诊断技术股份有限公司位于北京市海淀区永丰基地丰贤中路7号北科现代制造园孵化楼 一层、六层，成立日期2007年5月10日，上市日期2021年4月9日，公司主营业务涉及临床免疫化学发光 诊断检测试剂和仪器的研发、生产和销售。主营业务收入构成为：LiCA系列产品93.42%，CC系列产品 6.58%。 截至9月30日，科美诊断股东户数1.04万，较上期减少0.60%；人均流通股38586股，较上期增加0.61%。 2025年1月-9月，科美诊断实现营业收入2.61亿元，同比减少24.13%；归母净利润4156.28万元，同比减 少62.94%。 分红方面，科美诊断A股上市后累计派现3.06亿元。近三年，累计派现2.38亿元。 责任 ...

Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]

Group 1 - The core viewpoint of the news highlights the financial performance and trading activity of Kemei Diagnostics, indicating a decline in revenue and net profit for the first quarter of 2025 compared to the previous year [2] - As of August 26, Kemei Diagnostics experienced a financing net buy of -2.23 million yuan, with a total financing and securities balance of 206 million yuan, which is 5.86% of its market capitalization [1] - The company has a significant reliance on its LiCA series products, which account for 92.04% of its main business revenue [1] Group 2 - As of March 31, the number of shareholders for Kemei Diagnostics increased by 14.69% to 11,000, while the average circulating shares per person decreased by 12.81% to 36,384 shares [2] - For the first quarter of 2025, Kemei Diagnostics reported an operating income of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit attributable to shareholders of 14.54 million yuan, down 62.12% year-on-year [2] - The company has distributed a total of 306 million yuan in dividends since its A-share listing, with 238 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a decline in revenue and profit in the latest quarter [1] - Kemei Diagnostics' stock closed at 8.32 yuan, down 4.26%, with a rolling PE ratio of 32.33 times and a total market capitalization of 3.337 billion yuan [1] - The company ranks 66th in the medical device industry, which has an average PE ratio of 55.76 times and a median of 39.14 times [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company obtained 64 new domestic and international authorized patents during the reporting period, showcasing its innovation capability and technical reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Core Viewpoint - Company Kemei Diagnostics has shown a significant increase in shareholder numbers and continues to innovate in the medical diagnostics field, despite a decline in revenue and net profit in the latest quarterly report [1]. Group 1: Company Performance - As of August 7, Kemei Diagnostics closed at 8.62 yuan, up 1.65%, with a rolling PE ratio of 33.50 times and a total market capitalization of 3.458 billion yuan [1]. - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]. Group 2: Industry Comparison - The average PE ratio for the medical device industry is 54.79 times, with a median of 37.86 times, placing Kemei Diagnostics at the 68th position within the industry [1]. - The company’s static PE ratio is 27.21 times, and its price-to-book ratio is 2.42 times [2]. Group 3: Shareholder Information - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Group 4: Innovation and Patents - During the reporting period, Kemei Diagnostics obtained 64 new domestic and international patents, including 33 domestic invention patents, 20 utility model patents, and 11 design patents, indicating strong innovation capabilities and technical reserves [1].

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a decline in revenue and profit while showcasing its innovation capabilities through patent acquisitions [1][2]. Group 2 - Kemei Diagnostics closed at 8.6 yuan, down 1.83%, with a rolling PE ratio of 33.42 times and a total market value of 3.45 billion yuan [1]. - The average PE ratio for the medical device industry is 54.24 times, with a median of 37.92 times, placing Kemei Diagnostics at the 69th position in the industry ranking [1]. - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1]. - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products being the LiCA and CC series [1]. - During the reporting period, the company obtained 64 new domestic and international authorized patents, including 33 domestic invention patents, 20 domestic utility model patents, and 11 design patents, reflecting its growing innovation capability and technical reserves [1]. - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.30 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1].

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, indicating a significant drop in its stock price and earnings compared to industry averages [1][2] - Kemei Diagnostics closed at 8.76 yuan, with a PE ratio of 34.04, marking a new low in 367 days, and a total market capitalization of 3.514 billion yuan [1] - The average PE ratio for the medical device industry is 54.32, with a median of 38.11, placing Kemei Diagnostics at the 68th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average of 27,600 shares per shareholder [1] - The company specializes in the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5 million yuan, down 62.12%, with a gross margin of 66.88% [1]

Group 1 - The core viewpoint of the news is that Kemei Diagnostics has experienced a significant increase in stock price, reaching 8.49 yuan, up 6.66%, with a rolling PE ratio of 32.99, marking a new low in 113 days [1] - The total market capitalization of Kemei Diagnostics is 3.405 billion yuan, while the average PE ratio in the medical device industry is 53.65, and the median is 37.22, placing Kemei Diagnostics at the 68th position in the industry ranking [1] - As of March 31, 2025, Kemei Diagnostics has 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments, with major products including the LiCA series and CC series [1] - The company has obtained 64 new domestic and international authorized patents during the reporting period, including 33 domestic invention patents, 20 domestic utility model patents, and 11 design patents, indicating strong innovation capability and technical reserves [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kemei Diagnostics, indicating a significant decline in revenue and net profit in the latest quarterly report [1][2] - Kemei Diagnostics' stock closed at 7.99 yuan, with a rolling PE ratio of 31.05, marking a new low in 90 days, and a total market capitalization of 3.205 billion yuan [1] - The company ranks 63rd in the medical device industry, which has an average PE ratio of 55.28 and a median of 38.06 [1][2] Group 2 - As of March 31, 2025, Kemei Diagnostics had 11,024 shareholders, an increase of 1,412 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Kemei Diagnostics includes the research, development, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its growing innovation capability and technological reserves [1] Group 3 - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12%, with a gross profit margin of 66.88% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics, which has a current PE ratio of 30.46, significantly lower than the industry average of 54.56 [1][2] - Kemei Diagnostics has a total market capitalization of 3.145 billion yuan, ranking 62nd in the medical device industry based on PE ratio [1][2] - The company has seen an increase in shareholder numbers, with 11,024 shareholders as of March 31, 2025, an increase of 1,412 from the previous count [1] Group 2 - Kemei Diagnostics specializes in the research, development, production, and sales of clinical immunochemistry diagnostic reagents and instruments, with key products including the LiCA and CC series [1] - The company has demonstrated strong innovation capabilities, acquiring 64 new domestic and international patents during the reporting period, including 33 domestic invention patents [1] - In the latest quarterly report for Q1 2025, Kemei Diagnostics reported a revenue of 81.3 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.54 million yuan, down 62.12% [1]